TY  - JOUR
AU  - D'Ambrosio, Lorenzo
AU  - Touati, Nathan
AU  - Blay, Jean-Yves
AU  - Grignani, Giovanni
AU  - Flippot, Ronan
AU  - Czarnecka, Anna M
AU  - Piperno-Neumann, Sophie
AU  - Martin-Broto, Javier
AU  - Sanfilippo, Roberta
AU  - Katz, Daniela
AU  - Duffaud, Florence
AU  - Vincenzi, Bruno
AU  - Stark, Daniel P
AU  - Mazzeo, Filomena
AU  - Tuchscherer, Armin
AU  - Chevreau, Christine
AU  - Sherriff, Jenny
AU  - Estival, Anna
AU  - Litière, Saskia
AU  - Sents, Ward
AU  - Ray-Coquard, Isabelle
AU  - Tolomeo, Francesco
AU  - Le Cesne, Axel
AU  - Rutkowski, Piotr
AU  - Stacchiotti, Silvia
AU  - Kasper, Bernd
AU  - Gelderblom, Hans
AU  - Gronchi, Alessandro
AU  - European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
PY  - 2020
DO  - 10.1002/cncr.32795
UR  - http://hdl.handle.net/10668/15199
T2  - Cancer
AB  - The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as...
LA  - en
KW  - dacarbazine
KW  - doxorubicin
KW  - ifosfamide
KW  - leiomyosarcoma
KW  - propensity score
KW  - retrospective study
KW  - sarcoma
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Bone Neoplasms
KW  - Dacarbazine
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Ifosfamide
KW  - Leiomyosarcoma
KW  - Male
KW  - Middle Aged
KW  - Propensity Score
KW  - Retrospective Studies
KW  - Sarcoma
TI  - Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
TY  - research article
VL  - 126
ER  -